Mesa Laboratories vs Pacific Biosciences of California
MLAB and PACB side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MLAB and PACB compare
Mesa Laboratories is the larger company, worth 1.2 times as much as Pacific Biosciences of California ($779M against $650M).
Pacific Biosciences of California grew revenue faster over the last twelve months (4.4% versus 2.5% for Mesa Laboratories).
Mesa Laboratories keeps more of each dollar of sales as profit, with a net margin of 2.7% compared with −81.3% at Pacific Biosciences of California.
Mesa Laboratories pays a dividend yielding 0.46%; Pacific Biosciences of California does not pay one.
Mesa Laboratories scores higher on the StockData Score (11 against 3 for Pacific Biosciences of California), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MLAB | PACB |
|---|---|---|
| Size and price | ||
| Market cap | $779M | $650M |
| Share price | $139.21 | $2.09 |
| Change, 1 year | 70.1% | 18.8% |
| Change, 5 years | −55.4% | −92.1% |
| Beta (5Y) | 1.00 | 2.20 |
| Employees | 717 | 485 |
| StockData Score | ||
| Total score | 11 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 1 |
| Health score | 1 | 1 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 121× | – |
| P/S | 3.1× (better) | 4.0× |
| P/B | 4.0× | – |
| EV/EBITDA | 28.9× | – |
| P/FCF | 15.8× | – |
| PEG | 1.31 | – |
| FCF yield | 6.3% (better) | −22.1% |
| Fair value | $81.27 | – |
| Margin of safety | −71.3% | – |
| Growth | ||
| Revenue growth (TTM) | 2.5% | 4.4% (better) |
| Revenue growth, 5Y average | 13.2% | 15.2% (better) |
| EPS growth, 5Y average | 13.6% | – |
| Profitability | ||
| Gross margin | 64.8% (better) | 34.4% |
| Operating margin | 10.4% (better) | −81.3% |
| Net margin | 2.7% (better) | −81.3% |
| FCF margin | 19.7% (better) | −88.8% |
| Return on equity | 3.6% | – |
| Return on invested capital | 7.9% | – |
| Financial health | ||
| Interest coverage | 2.6× (better) | −17.2× |
| Current ratio | 1.90 | 4.62 (better) |
| Altman Z-score | 2.54 (better) | −4.89 |
| Piotroski F-score | 8 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.46% (better) | 0.00% |
| Payout ratio | 53.3% | – |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | 0.00% | – |
| Shareholder yield | 0.46% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 89.9% | 61.5% |
| Held by insiders | 3.6% | 4.3% |
| Insider net buying, 12 months | −$216K (better) | −$3.4M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 7.0% | 18.1% |
Go deeper
- MLAB stock overview
- MLAB income statement
- MLAB valuation and score
- PACB stock overview
- PACB income statement
- PACB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.